Find Your Broker
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.80p -2.94% 26.45p 26.00p 26.90p 26.60p 26.00p 26.60p 219,581 16:35:21
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 41.6 4.3 59.0 0.4 121.04

Ekf Diagnostics Share Discussion Threads

Showing 1526 to 1548 of 1550 messages
Chat Pages: 62  61  60  59  58  57  56  55  54  53  52  51  Older
DateSubjectAuthorDiscuss
07/12/2018
12:05
Indeed, and the buybacks are ahead of the realisation from certain growth initiatives!
wan
07/12/2018
11:44
thanks wan well spotted . The share buyback seems to be happening on a daily basisi
9degrees
15/11/2018
16:38
Anyone know what ratio to use to work out the cost of the shares in Renx we have received.
the shuffle man
09/11/2018
19:32
Huge £300k+ director sale today
dan_the_epic
09/11/2018
13:20
9Degrees...that is correct, which is exactly what EKF have already detailed. Excerpt - Relevant EKF Shareholders will become the beneficial and legal owners of their respective Distribution Shares when the Board resolves to declare the distribution in specie, at which time an 'omnibus' share certificate in respect of the Distribution Shares will be issued, to be held on behalf of the Relevant EKF Shareholders by a custodian for a period of 180 days from the date of the Distribution (the “Lock-up Period”). Relevant EKF Shareholders will receive a letter informing them of their holdings of RENX Shares shortly after the declaration of the Distribution. The Board expects to declare the Distribution on or around 24 October. Following the Lock-up Period, Relevant EKF Shareholders will receive individual certificates in respect of their Distribution Shares, which they will have the option to dematerialise. The Lock-up Period is intended to contribute to the creation of an orderly market in RENX Shares at and for a period after RenalytixAI’s admission to trading on AIM, where obtaining signed lock-ups from all of the Relevant EKF shareholders in respect of their Distribution Shares would not have been possible. Full release - hTTps://www.ekfdiagnostics.com/approval-of-distribution-of-shares-in-renalytixai.html
wan
09/11/2018
12:31
am I right in reading that we cannot sell RENX shares until 22 April 2019? This is what Barclays Smart investor is telling me
9degrees
07/11/2018
16:42
Yes, they're being a bit slow! CD
cambridgedon
07/11/2018
16:25
Portfolio still not showing XR holding or open offer holding on AJ Bell.
wilsonst1
06/11/2018
12:29
I am seriously considering transferring to another platform.
wan
06/11/2018
11:48
barclays smart investor slow slow as ever
9degrees
06/11/2018
10:29
Nothing showing on A J Bell site. CD
cambridgedon
06/11/2018
09:22
Despite being told by Barclays Smart Investor (in writing) that Renalytix shares would be available on their platform when they commence trading, entering Renalytix, RENX or ISIN GB00BYWL4Y04 just results in the following message "There are no investments to display". I am currently awaiting a response (to yet another complaint!). Anyone else having issues with other platforms?
wan
06/11/2018
07:41
wakey wakey hands off snakey took the liberty of creating a RENX thread seeing as there isn't one already hTtp://uk.advfn.com/cmn/fbb/thread.php3?id=43477962
the stigologist
02/11/2018
08:34
AIM admission date for RENX is 6th November. CD
cambridgedon
29/10/2018
07:57
Thanks Wan. My sentiments exactly. CD
cambridgedon
28/10/2018
06:56
Cambridgedon...If we take 40p (Market cap £183m) as having fully realised, in share price terms, the soluble Tumor Necrosis Factor Receptors 1 and 2 (sTNFR1/2) biomarker assets, and then factor in EKF receiving in round figures £25m (20,964,524 RENX Shares @ £1.21) for those assets, that should result in a ex distribution share price (reduction) to circa 35p (market cap £160m) However, 40p may have been driven by increased demand ahead of the spin-out, but even if we targeted 35p as discounting the effects of such demand, then we would arrive at an ex distribution share price of 30p (hence previous comments) From the point of announcing the spin-out (11th Jan 2018 share price circa 26p), if one looks at specific announcements and other stated growth initiatives, which are over and above that associated with Renaltix, then there is very good reason to expect an increase in organic growth over the near term and a significant increase in growth over the medium term.
wan
26/10/2018
11:29
Just added some more at 26.8p The drop makes little sense as far as I can see. Anyone have a POV? CD
cambridgedon
25/10/2018
20:21
Smart(?) investor too. Disappointed.
nightmare trader
25/10/2018
10:35
I suggest you complain to FCA as this is plainly not acting in the best interests of customers.
intrinsicinvestor
24/10/2018
13:01
I have been officially informed this afternoon that Barclays Smart Investor has made "a business decision" not to make available the restricted share offer in Renalytix to EKF shareholders. So unfortunately I (and certain other shareholders) cannot partake, which I feel both disappointed and aggrieved about!
wan
23/10/2018
14:34
Macarona...As discussed on here previously, the current EKF share price appears to have already reflected the distribution, presumably because the announcements had effectively flagged when and by how much, but as I said this morning, time will tell None of us can predict what will happen when Renalytix commences trading, but having done quite a bit of research I am quite hopeful about the near to medium term prospects for Renalytix (including potential news flow), and maybe there will be good demand for the shares (other AI in healthcare companies are certainly attaining very high valuations). So my decision to buy more EKF shares was based on the current share price pullback and the near term prospects and potential news flow for EKF, and also about getting the maximum exposure to Renalytix ahead of any high demand and potentially being scaled back on the Restricted Offer, via which I intend to also add (and possibly when trading commences too). Best wishes to all EKF and Renalytix shareholders.
wan
23/10/2018
13:00
I really hope it does not fall further tomorrow, as that would be ex distribution date.
macarona
23/10/2018
09:53
Macarona...You have to own at least 22 EKF shares and have enough to be divisible above that, so there is your threshold.
wan
Chat Pages: 62  61  60  59  58  57  56  55  54  53  52  51  Older
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20181213 06:08:14